|Day Low/High||154.03 / 155.30|
|52 Wk Low/High||96.14 / 155.13|
Masimo (NASDAQ: MASI) announced today that in a study recently published in Anesthesia & Analgesia, researchers investigated the incidence of isoelectric electroencephalogram (EEG) events in infants and young children undergoing scheduled surgery...
Masimo (NASDAQ: MASI) announced today that O3 ® Regional Oximetry has received FDA clearance for use on neonatal and infant patients (<10 kg).
Masimo (NASDAQ: MASI) announced today that NuVision Management Healthcare Consulting Company, a pediatric and adult healthcare consulting company, is adopting a comprehensive variety of Masimo technologies at its three pediatric care facilities in New...
Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb ® to...
Masimo (NASDAQ: MASI) is hosting an Investor Day at its headquarters in Irvine today, which will include presentations by Chairman and Chief Executive Officer Joe Kiani and other members of the executive team.
Masimo (NASDAQ: MASI) announced today FDA 510(k) clearance of Radius PPG, a tetherless sensor solution powered by Masimo SET ® that represents a significant breakthrough in patient monitoring.
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the UBS Global Healthcare Conference at the Grand Hyatt New York on Tuesday, May 21, 2019 at 2:00 p.
Masimo (NASDAQ: MASI) and Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Masimo (Nasdaq: MASI) today announced its financial results for the first quarter ended March 30, 2019.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Masimo Corp. , where a total volume of 2,548 contracts has been traded thus far today, a contract volume which is representative of approximately 254,800 underlying shares (given that every 1 contract represents 100 underlying shares).
Masimo (NASDAQ: MASI) announced today that after a decade of developing and testing its comprehensive, scalable, and customizable continuous early warning score, with the aid of leading expert clinicians around the world, it is releasing Halo ION™.
Masimo (NASDAQ: MASI) and Mdoloris Medical Systems announced today the CE marking of the Mdoloris Analgesia Nociception Index (ANI ®) module for the Masimo Root ® Patient Monitoring and Connectivity Hub, the first commercially available result of a Masimo...
Masimo (NASDAQ: MASI) announced today that it will release first quarter 2019 financial results for the period ended March 30, 2019, after the market closes on Monday, May 6, 2019.
Masimo (NASDAQ: MASI) announced today the findings of a study, recently published in Anaesthesia and Intensive Care, in which researchers at Austin Hospital in Melbourne, Australia sought to measure cerebral oxygenation in a large cohort of healthy...
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the 18th Annual Needham Healthcare Conference at the Westin Grand Central Hotel in New York on Tuesday, April 9, 2019 at 12:50 p.
Masimo (NASDAQ: MASI) announced today FDA clearance of the Rad-67™ Pulse CO-Oximeter ® with Spot-check Next Generation SpHb ® monitoring technology and the rainbow ® DCI ®-mini Reusable Sensor.
St. Luke's University Health Network (St.
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on Wednesday, March 13, 2019 at 4:50 p.
Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine ® brain function monitoring for pediatric patients (1-18 years of age).
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Raymond James 40th Annual Institutional Investors Conference at the J.
Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full year ended December 29, 2018.
Masimo (NASDAQ: MASI) announced today the findings of a series of four clinical cases, recently published in the Canadian Journal of Anesthesiology, in which researchers at the University of Montreal found that combined use of Masimo SedLine ® brain...
Recently at Arab Health 2019, the Saudi Arabia Ministry of Health (MOH) and Masimo (NASDAQ: MASI) jointly announced the implementation of an automation solution designed to streamline the process of critical congenital heart disease (CCHD) screening of...
Masimo (NASDAQ: MASI) announced today the launch of Doctella™, a home-based patient engagement and remote care automation platform.
Masimo (NASDAQ: MASI) announced today FDA clearance of the measurement of respiration rate from the pleth (RRp ®) on the MightySat™ Rx spot-check fingertip pulse oximeter, as well as its indication for use in the home environment.
Masimo (NASDAQ: MASI) announced today the U.S.
Masimo Corporation (NASDAQ: MASI) today announced select preliminary results for the full year December 29, 2018 and provided estimates for its full year 2019 financial guidance.
Masimo (NASDAQ: MASI), a global medical technology developer and manufacturer of innovative noninvasive patient monitoring technologies, announced today that Julie A.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.